NO20081071L - Makrocykliske inhibitorer av hepatitt C virus - Google Patents

Makrocykliske inhibitorer av hepatitt C virus

Info

Publication number: NO20081071L
Authority: NO; Norway
Prior art keywords: hepatitis; virus; inhibitors; macrocyclic inhibitors; formula
Prior art date: 2005-07-29

Application number

NO20081071A

Other languages

English (en)

Norwegian (no)

Inventor

Herman Augustinus De Kock

Abdellah Tahri

Pierre Jean-Marie Raboisson

Kenneth Alan Simmen

Sandrine Marie Helene Vendeville

Lili Hu

Wim Van De Vreken

David Craig Mcgowan

Dominique Louis Nestor Surleraux

Original Assignee

Tibotec Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-29

Filing date

2008-02-29

Publication date

2008-04-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37036843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081071(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-29 Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd

2008-04-25 Publication of NO20081071L publication Critical patent/NO20081071L/no

Links

239000003112 inhibitor Substances 0.000 title abstract 3
241000711549 Hepacivirus C Species 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
229960000311 ritonavir Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20081071A 2005-07-29 2008-02-29 Makrocykliske inhibitorer av hepatitt C virus NO20081071L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05107067		2005-07-29
EP05107413		2005-08-11
PCT/EP2006/064813 WO2007014919A1 (en)	2005-07-29	2006-07-28	Macrocylic inhibitors of hepatitis c virus

Publications (1)

Publication Number	Publication Date
NO20081071L true NO20081071L (no)	2008-04-25

Family

ID=37036843

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20081071A NO20081071L (no)	2005-07-29	2008-02-29	Makrocykliske inhibitorer av hepatitt C virus

Country Status (27)

Country	Link
US (1)	US7989471B2 (pt)
EP (1)	EP1912995B1 (pt)
JP (1)	JP5426163B2 (pt)
KR (1)	KR101074673B1 (pt)
CN (1)	CN101233137B (pt)
AP (1)	AP2473A (pt)
AR (1)	AR055104A1 (pt)
AT (1)	ATE517902T1 (pt)
AU (1)	AU2006274858B2 (pt)
BR (1)	BRPI0614670A2 (pt)
CA (1)	CA2617095C (pt)
DK (1)	DK1912995T3 (pt)
EA (1)	EA014646B1 (pt)
GT (1)	GT200600341A (pt)
IL (1)	IL188283A (pt)
JO (1)	JO2768B1 (pt)
MX (1)	MX2008001395A (pt)
MY (1)	MY152153A (pt)
NO (1)	NO20081071L (pt)
NZ (1)	NZ564541A (pt)
PE (1)	PE20070221A1 (pt)
SG (1)	SG163613A1 (pt)
SI (1)	SI1912995T1 (pt)
SV (1)	SV2008002639A (pt)
TW (1)	TWI412534B (pt)
UY (1)	UY29705A1 (pt)
WO (1)	WO2007014919A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
PL1713822T3 (pl)	2004-01-30	2010-08-31	Medivir Ab	Inhibitory proteazy serynowej HCV NS-3
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en)	2005-11-03	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
RU2008152171A (ru) *	2006-07-05	2010-08-10	Интермьюн, Инк. (Us)	Новые ингибиторы вирусной репликации гепатита с
US7935670B2 (en)	2006-07-11	2011-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
PT2041156E (pt)	2006-07-13	2014-02-21	Achillion Pharmaceuticals Inc	Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral
US8343477B2 (en)	2006-11-01	2013-01-01	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7772180B2 (en)	2006-11-09	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2008070358A2 (en) *	2006-11-16	2008-06-12	Phenomix Corporation	N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US7888464B2 (en)	2006-11-16	2011-02-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7763584B2 (en)	2006-11-16	2010-07-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8003604B2 (en)	2006-11-16	2011-08-23	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2008086161A1 (en) *	2007-01-08	2008-07-17	Phenomix Corporation	Macrocyclic hepatitis c protease inhibitors
CN101641349A (zh) *	2007-02-08	2010-02-03	泰博特克药品有限公司	嘧啶取代的大环抑制剂
WO2008096002A1 (en) *	2007-02-08	2008-08-14	Tibotec Pharmaceuticals Ltd.	Hcv inhibiting macrocyclic phosphonates and amidophosphates
US8383583B2 (en)	2007-10-26	2013-02-26	Enanta Pharmaceuticals, Inc.	Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8304385B2 (en)	2007-11-14	2012-11-06	Enanta Pharmaceuticals, Inc.	Macrocyclic tetrazolyl hepatitis C serine protease inhibitors
WO2009079353A1 (en)	2007-12-14	2009-06-25	Enanta Pharmaceuticals, Inc.	Triazole-containing macrocyclic hcv serine protease inhibitors
US8202996B2 (en)	2007-12-21	2012-06-19	Bristol-Myers Squibb Company	Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CN102015652A (zh)	2008-03-20	2011-04-13	益安药业	作为丙型肝炎病毒抑制剂的氟化大环化合物
US8163921B2 (en)	2008-04-16	2012-04-24	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7964560B2 (en)	2008-05-29	2011-06-21	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2300491B1 (en)	2008-05-29	2016-01-06	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US8207341B2 (en)	2008-09-04	2012-06-26	Bristol-Myers Squibb Company	Process or synthesizing substituted isoquinolines
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en)	2008-09-29	2013-10-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8044087B2 (en)	2008-09-29	2011-10-25	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2364309B1 (en)	2008-12-10	2014-10-01	Achillion Pharmaceuticals, Inc.	New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en)	2008-12-15	2012-10-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201040181A (en)	2009-04-08	2010-11-16	Idenix Pharmaceuticals Inc	Macrocyclic serine protease inhibitors
US8232246B2 (en)	2009-06-30	2012-07-31	Abbott Laboratories	Anti-viral compounds
CN101987825B (zh) *	2009-07-31	2014-04-02	上海开拓者医药发展有限公司	一种2-氨基-3-甲基-4-甲氧基苯乙酮的制备方法
EP2461811B1 (en)	2009-08-05	2016-04-20	Idenix Pharmaceuticals LLC.	Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
EP2658859A4 (en)	2010-12-30	2014-07-30	Enanta Pharm Inc	MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
KR20140003521A (ko)	2010-12-30	2014-01-09	이난타 파마슈티칼스, 인코포레이티드	페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
AR085352A1 (es)	2011-02-10	2013-09-25	Idenix Pharmaceuticals Inc	Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8691757B2 (en)	2011-06-15	2014-04-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2863002A1 (en) *	2012-01-11	2013-07-18	Abbvie Inc.	Processes for making hcv protease inhibitors
EP2903988A1 (en)	2012-10-08	2015-08-12	AbbVie Inc.	Compounds useful for making hcv protease inhibitors
EA025560B1 (ru)	2012-10-19	2017-01-30	Бристол-Майерс Сквибб Компани	Ингибиторы вируса гепатита с
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2014070964A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014071007A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
EP2914614B1 (en)	2012-11-05	2017-08-16	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014137869A1 (en)	2013-03-07	2014-09-12	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
CA2905433A1 (en)	2013-03-14	2014-09-25	Achillion Pharmaceuticals, Inc.	Novel processes for producing sovaprevir
WO2014145507A1 (en)	2013-03-15	2014-09-18	Achillion Pharmaceuticals, Inc.	A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en)	2013-03-15	2015-07-21	Achillion Pharmaceuticals, Inc.	ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
BR112015023351A2 (pt)	2013-03-15	2017-07-18	Achillion Pharmaceuticals Inc	forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
MA41812A (fr) *	2015-03-27	2018-01-30	Janssen Pharmaceuticals Inc	Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1302468B1 (en)	1992-12-29	2008-12-17	Abbott Laboratories	Processes and intermediates for manufacturing retroviral protease inhibiting compounds
IL110752A (en)	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en)	1993-10-01	1996-09-24	Abbott Laboratories	Pharmaceutical composition
IL111991A (en)	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en)	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
US5807876A (en)	1996-04-23	1998-09-15	Vertex Pharmaceuticals Incorporated	Inhibitors of IMPDH enzyme
US6054472A (en)	1996-04-23	2000-04-25	Vertex Pharmaceuticals, Incorporated	Inhibitors of IMPDH enzyme
CA2252465C (en)	1996-04-23	2007-07-03	Vertex Pharmaceuticals Incorporated	Urea derivatives as inhibitors of impdh enzyme
AP1019A (en)	1996-10-18	2001-10-16	Vertex Pharma	Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
DK0966465T3 (da)	1997-03-14	2003-10-20	Vertex Pharma	Inhibitorer af IMPDH-enzymer
EP1012180B1 (en)	1997-08-11	2004-12-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor peptide analogues
GB9818731D0 (en) *	1998-08-27	1998-10-21	Univ Portsmouth	Compounds
CA2367017C (en)	1999-03-19	2009-05-26	Vertex Pharmaceuticals Incorporated	Inhibitors of impdh enzyme
UA74546C2 (en) *	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2003223602B8 (en)	2002-04-11	2010-05-27	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
ES2320771T3 (es) *	2003-04-16	2009-05-28	Bristol-Myers Squibb Company	Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
US7125845B2 (en) *	2003-07-03	2006-10-24	Enanta Pharmaceuticals, Inc.	Aza-peptide macrocyclic hepatitis C serine protease inhibitors
PL1713822T3 (pl)	2004-01-30	2010-08-31	Medivir Ab	Inhibitory proteazy serynowej HCV NS-3
PE20070343A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Inhibidores macrociclicos del virus de la hepatitis c
TWI375670B (en) *	2005-07-29	2012-11-01	Tibotec Pharm Ltd	Macrocylic inhibitors of hepatitis c virus

2006
- 2006-07-19 JO JO2006237A patent/JO2768B1/en active
- 2006-07-26 PE PE2006000917A patent/PE20070221A1/es not_active Application Discontinuation
- 2006-07-28 GT GT200600341A patent/GT200600341A/es unknown
- 2006-07-28 AT AT06764264T patent/ATE517902T1/de active
- 2006-07-28 CA CA2617095A patent/CA2617095C/en not_active Expired - Fee Related
- 2006-07-28 WO PCT/EP2006/064813 patent/WO2007014919A1/en not_active Ceased
- 2006-07-28 TW TW095127588A patent/TWI412534B/zh not_active IP Right Cessation
- 2006-07-28 EP EP06764264A patent/EP1912995B1/en active Active
- 2006-07-28 SG SG201005107-6A patent/SG163613A1/en unknown
- 2006-07-28 CN CN200680027654.7A patent/CN101233137B/zh not_active Expired - Fee Related
- 2006-07-28 UY UY29705A patent/UY29705A1/es unknown
- 2006-07-28 SI SI200631129T patent/SI1912995T1/sl unknown
- 2006-07-28 JP JP2008523375A patent/JP5426163B2/ja not_active Expired - Fee Related
- 2006-07-28 DK DK06764264.5T patent/DK1912995T3/da active
- 2006-07-28 MY MYPI20063671 patent/MY152153A/en unknown
- 2006-07-28 EA EA200800484A patent/EA014646B1/ru not_active IP Right Cessation
- 2006-07-28 AP AP2008004305A patent/AP2473A/xx active
- 2006-07-28 NZ NZ564541A patent/NZ564541A/en not_active IP Right Cessation
- 2006-07-28 AU AU2006274858A patent/AU2006274858B2/en not_active Ceased
- 2006-07-28 US US11/995,573 patent/US7989471B2/en not_active Expired - Fee Related
- 2006-07-28 BR BRPI0614670-8A patent/BRPI0614670A2/pt not_active Application Discontinuation
- 2006-07-28 MX MX2008001395A patent/MX2008001395A/es active IP Right Grant
- 2006-07-28 AR ARP060103306A patent/AR055104A1/es unknown
- 2006-07-28 KR KR1020087003833A patent/KR101074673B1/ko not_active Expired - Fee Related
- 2006-07-29 SV SV2006002639A patent/SV2008002639A/es unknown
2007
- 2007-12-20 IL IL188283A patent/IL188283A/en not_active IP Right Cessation
2008
- 2008-02-29 NO NO20081071A patent/NO20081071L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EA014646B1 (ru)	2010-12-30
US20100240698A1 (en)	2010-09-23
EA200800484A1 (ru)	2008-06-30
CN101233137A (zh)	2008-07-30
US7989471B2 (en)	2011-08-02
SV2008002639A (es)	2008-07-23
CN101233137B (zh)	2014-05-07
GT200600341A (es)	2007-02-26
PE20070221A1 (es)	2007-04-16
EP1912995B1 (en)	2011-07-27
IL188283A0 (en)	2008-04-13
AU2006274858B2 (en)	2012-05-24
HK1116772A1 (en)	2009-01-02
UY29705A1 (es)	2007-05-31
MY152153A (en)	2014-08-15
ATE517902T1 (de)	2011-08-15
BRPI0614670A2 (pt)	2011-04-12
NZ564541A (en)	2010-03-26
SI1912995T1 (sl)	2011-11-30
DK1912995T3 (da)	2011-10-24
AR055104A1 (es)	2007-08-08
WO2007014919A1 (en)	2007-02-08
CA2617095A1 (en)	2007-02-08
EP1912995A1 (en)	2008-04-23
IL188283A (en)	2016-12-29
AU2006274858A1 (en)	2007-02-08
TW200745165A (en)	2007-12-16
JP2009502882A (ja)	2009-01-29
KR20080041651A (ko)	2008-05-13
CA2617095C (en)	2014-05-13
KR101074673B1 (ko)	2011-10-19
AP2473A (en)	2012-09-24
TWI412534B (zh)	2013-10-21
JP5426163B2 (ja)	2014-02-26
JO2768B1 (en)	2014-03-15
SG163613A1 (en)	2010-08-30
MX2008001395A (es)	2008-04-16

Legal Events

Date	Code	Title	Description
2016-02-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20081071L (no)	2008-04-25	Makrocykliske inhibitorer av hepatitt C virus
NO20081073L (no)	2008-04-28	Makrocykliske inhibitorer av hepatitt C virus
EP1924593B8 (en)	2009-11-18	Hcv ns3 protease inhibitors
EP2041159B8 (en)	2012-02-22	Macrocyclic compounds as antiviral agents
WO2006119061A3 (en)	2007-01-25	Hcv ns3 protease inhibitors
TW200639169A (en)	2006-11-16	Bicyclic heteroaryl derivatives for treating viruses
WO2008057208A3 (en)	2008-10-30	Hcv ns3 protease inhibitors
WO2008051514A3 (en)	2008-06-19	Hcv ns3 protease inhibitors
WO2008051475A3 (en)	2008-11-20	Hcv ns3 protease inhibitors
WO2008051477A3 (en)	2008-10-16	Hcv ns3 protease inhibitors
MY164469A (en)	2017-12-15	Hcv ns3 protease inhibitors
NO20081074L (no)	2008-04-29	Macrocyclisk inhibitorer av hepatitis C-virus
MY152070A (en)	2014-08-15	Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
CU23787B7 (es)	2012-03-15	Compuestos macrocíclicos como inhibidores de la replicación viral
WO2013074386A3 (en)	2015-06-18	Hcv ns3 protease inhibitors
NO20090628L (no)	2009-04-21	Pyridizinon derivativater
IL182315A0 (en)	2007-07-24	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
TW200602064A (en)	2006-01-16	Nucleoside derivatives for treating hepatitis C virus infection
UA83046C2 (ru)	2008-06-10	Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
WO2005035525A3 (en)	2005-10-20	2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
IL195025A (en)	2013-09-30	History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
WO2007041487A3 (en)	2007-07-26	Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2007084435A8 (en)	2009-11-12	Methods for treating hepatitis c
WO2007120374A3 (en)	2008-04-10	Anti-arenaviral compounds
WO2010034105A8 (en)	2011-01-06	Hepatitis c inhibitor compounds